Tempus AI, Inc. (TEM)
Tempus AI: Buy The Post-Earnings Dip
Tempus AI maintains strong Q4 momentum, with robust testing stats and improving financials despite recent post-earnings stock weakness. Oncology testing volume grew 29% YoY, and net revenue retention reached 126%, signaling strong customer value and recurring demand. Adjusted EBITDA turned positive in Q4, and 2026 guidance projects $65M adjusted EBITDA, though revenue growth is expected to slow to 25%.
Tempus AI Sold Off After a Beat—But the Rebound Case Is Building
Tempus AI NASDAQ: TEM appears to be a smart buy for tech traders as it is a leading provider of AI-enabled services and infrastructure for healthcare, and its stock is set up to rebound robustly. Trading near 52-week lows in late February, the stock is more than 45% below the analysts' consensus, with tailwinds to drive it there.
Tempus AI: No AI Interruption Detected
Tempus AI, Inc. has declined 50% from highs, now trading near support despite robust above $50, despite good Q4 results and strong organic growth. The AI precision medicine company delivered 33% organic growth with Diagnostics revenue expanding due to higher test ASPs. Concerns over AI replacement have pressured the stock, yet TEM's proprietary data and hospital network provide defensible moats.
TEM Q4 Earnings Miss, Revenues Beat, Stock Down in After-Market
Tempus AI posts Q4 revenue beat with 83% surge, but wider-than-expected loss and operating shortfall send shares down in after-hours trading.
Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript
Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript
Tempus AI (TEM) Reports Q4 Loss, Beats Revenue Estimates
Tempus AI (TEM) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.18 per share a year ago.
Live Earnings: Will Tempus AI Surprise Wall Street Tonight?
We are updating this story in real time as new information breaks. Stay on this page for the latest developments, key quotes, numbers, and market reaction as they happen.
Here's How Tempus AI Is Tapping the Imagining Space
TEM expands into radiology via Median partnership, adding AI lung screening to Pixel as FDA clearance and past deals boost imaging push.
AI-Driven Innovation Accelerates Tempus AI's Expansion Across MedTech
TEM rolls out new AI tools across oncology, cardiology and mental health, accelerating its push to reshape MedTech innovation.
Is TEM Stock A Buy At $60?
Tempus AI (NASDAQ: TEM) trades at a premium by traditional metrics, remains unprofitable on a GAAP basis, and has spent the past week benefiting from strong analyst optimism. So why might the stock still appear attractive at $60?
Unlocking Q4 Potential of Tempus (TEM): Exploring Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Tempus (TEM) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week's Earnings
Tempus AI, Inc. (NASDAQ:TEM) shares are climbing today after the company unveiled a new AI-powered cancer diagnostic algorithm, building momentum ahead of its Q4 2025 earnings report scheduled for February 24, 2026 after market close.
